We are live on !
Find out more
Aperio Group Portfolio holdings
AUM
$33.8B
Turnover
6.32%
1-Year Est. Return
31.46%
This Fund
S&P 500
This Quarter Est. Return
+15.94%
1 Year Est. Return
+31.46%
3 Year Est. Return
+70.41%
5 Year Est. Return
+146.06%
10 Year Est. Return
–
AUM
$33.8B
AUM Growth
+$4.19B
(+14%)
Cap. Flow
+$264M
Cap. Flow % of AUM
Cap. Flow %
0.78%
Top 10 Holdings %
Top 10 Hldgs %
21.76%
Holding
2,483
New
104
Increased
1,329
Reduced
987
Closed
53
Avg Time Held
4.6
years
Top 10 Avg Time Held
3.4
years
Top 20 Avg Time Held
3.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Unilever
UL
|
+$52.4M |
| 2 |
Tesla
TSLA
|
+$42.1M |
| 3 |
Microsoft
MSFT
|
+$16.9M |
| 4 |
Walt Disney
DIS
|
+$14.5M |
| 5 |
Morgan Stanley
MS
|
+$11.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Unilever NV New York Registry Shares
UN
|
+$48.8M |
| 2 |
AT&T
T
|
+$25.4M |
| 3 |
Johnson & Johnson
JNJ
|
+$20M |
| 4 |
Amazon
AMZN
|
+$15.7M |
| 5 |
Biogen
BIIB
|
+$12.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.68% |
| 2 | Financials | 13.75% |
| 3 | Healthcare | 13.35% |
| 4 | Consumer Discretionary | 11.59% |
| 5 | Communication Services | 9.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
RRD
2376
DELISTED
RR Donnelley & Sons Co.
RRD
| $109K | ﹤0.01% |
48,293
+1,802
| +4% | +$2.71K |
2016 Q4
16 quarters
|
|
2377
Oil States International
OIS
$500M
| $108K | ﹤0.01% |
21,591
+111
| +0.5% | +$430 |
2014 Q1
27 quarters
|
|
2378
Alaunos Therapeutics
TCRT
$7.55M
| $104K | ﹤0.01% |
274
+90
| +49% | +$35.8K |
2020 Q1
3 quarters
|
|
2379
Puma Biotechnology
PBYI
$555M
| $103K | ﹤0.01% |
10,068
-5,971
| -37% | -$60.5K |
2020 Q3
1 quarter
|
|
2380
KALA BIO
KALA
$3.67M
| $100K | ﹤0.01% |
6
+2
| +50% | +$37.6K |
2020 Q3
1 quarter
|
|
|
PTNR
2381
DELISTED
Partner Communications
PTNR
| $97K | ﹤0.01% |
18,045
-584
| -3% | -$2.68K |
2014 Q1
27 quarters
|
|
|
QEP
2382
DELISTED
QEP RESOURCES, INC.
QEP
| $97K | ﹤0.01% |
40,693
-30,051
| -42% | -$44.5K |
2014 Q1
27 quarters
|
|
|
GSH
2383
DELISTED
Guangshen Railway Co. Ltd
GSH
| $93K | ﹤0.01% |
10,315
-3,247
| -24% | -$28.4K |
2014 Q1
27 quarters
|
|
|
CLVS
2384
DELISTED
Clovis Oncology, Inc.
CLVS
| $91K | ﹤0.01% |
18,924
-32,087
| -63% | -$162K |
2020 Q1
3 quarters
|
|
|
CPLG
2385
DELISTED
CorePoint Lodging Inc. Common Stock
CPLG
| $88K | ﹤0.01% |
12,832
-1,648
| -11% | -$10K |
2020 Q3
1 quarter
|
|
|
BDSI
2386
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $88K | ﹤0.01% |
20,877
-6,448
| -24% | -$24.8K |
2020 Q2
2 quarters
|
|
2387
DELISTED
Farmer Brothers
FARM
| $84K | ﹤0.01% |
18,075
-3,822
| -17% | -$16.4K |
2017 Q1
15 quarters
|
|
2388
Voyager Therapeutics
VYGR
$135M
| $81K | ﹤0.01% |
11,266
-1,539
| -12% | -$14.8K |
2020 Q3
1 quarter
|
|
2389
Assembly Biosciences
ASMB
$431M
| $80K | ﹤0.01% |
1,110
-157
| -12% | -$18.4K |
2020 Q1
3 quarters
|
|
|
ACGN
2390
DELISTED
Aceragen Inc
ACGN
| $77K | ﹤0.01% |
1,243
| – | – |
2020 Q1
3 quarters
|
|
|
AUD
2391
DELISTED
Audacy, Inc.
AUD
| $77K | ﹤0.01% |
31,025
+5,809
| +23% | +$11.9K |
2017 Q2
14 quarters
|
|
2392
DELISTED
Edgio, Inc. Common Stock
EGIO
| $76K | ﹤0.01% |
+477
| New | +$87.2K |
2020 Q4
0 quarters
|
|
|
CALA
2393
DELISTED
Calithera Biosciences, Inc
CALA
| $76K | ﹤0.01% |
+777
| New | +$68.1K |
2020 Q4
0 quarters
|
|
2394
Geron
GERN
$797M
| $75K | ﹤0.01% |
47,377
+29,117
| +159% | +$53K |
2020 Q2
2 quarters
|
|
2395
Ardelyx
ARDX
$829M
| $74K | ﹤0.01% |
+11,401
| New | +$67.7K |
2020 Q4
0 quarters
|
|
|
SNR
2396
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
| $73K | ﹤0.01% |
+14,151
| New | +$69.1K |
2020 Q4
0 quarters
|
|
2397
Comstock Resources
CRK
$4.15B
| $69K | ﹤0.01% |
15,715
-7,228
| -32% | -$35.8K |
2020 Q1
3 quarters
|
|
2398
SunCoke Energy
SXC
$833M
| $67K | ﹤0.01% |
+15,516
| New | +$64.9K |
2020 Q4
0 quarters
|
|
|
HMHC
2399
DELISTED
Houghton Mifflin Harcourt Company
HMHC
| $67K | ﹤0.01% |
+20,092
| New | +$59.8K |
2020 Q4
0 quarters
|
|
2400
TherapeuticsMD
TXMD
$21.8M
| $65K | ﹤0.01% |
1,077
+19
| +2% | +$1.3K |
2016 Q3
17 quarters
|
|
Similar funds
LCM
Aperio Group's Q4 2020 Portfolio in Review
As of Q4 2020, Aperio Group held 2,483 positions worth $33.8B, up 14% from $29.6B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Aperio Group's Q4 2020 filing shows 104 new, 1,329 increased, 987 reduced and 53 closed positions. Its largest new stake was Concentrix: 51,604 shares worth $5.09M. The largest sale was Unilever NV New York Registry Shares, an estimated $48.8M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 26% a quarter earlier, followed by Financials and Healthcare.
- Aperio Group's largest Q4 2020 buy was Concentrix: 51,604 shares worth $5.09M.
- Aperio Group added most to Unilever in Q4 2020, an estimated $52.4M increase.
- Aperio Group's biggest Q4 2020 reduction was AT&T, cutting an estimated $25.4M.
- Aperio Group fully exited Unilever NV New York Registry Shares in Q4 2020, selling an estimated $48.8M.
- Aperio Group's ten largest holdings make up 22% of its $33.8B portfolio in Q4 2020.
- Aperio Group opened 104 new positions and closed 53 in Q4 2020.
- Aperio Group's portfolio value rose 14% quarter-over-quarter to $33.8B.
Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.